gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MDGLHealthcarePharmaceuticals

Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)

$400.43+1.04%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$400.43▼ 9.94% in range
Nov 4, 2025Low $396.32 · High $602.83Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Madrigal Pharmaceuticals closed at $400.43 on Nov 4, up 1.04%, within 1.0% of its 52-week closing low. Volume of 2.3M shares was 5.84× its 20-day average (well above normal).

Split-adjusted performance: -19.3% over one month, -25.8% over six months, -2.9% over one year.

In the quarter ended Sep 30, 2026, revenue was $431.27M, up 50.1% from a year earlier, with a net margin of 12.9%.

Short interest was 2.2M shares at the Oct 15 settlement, down 8.4% from the prior report (14.7% of float, 7.2 days to cover).

Market cap$9.25B23.1M shares
Revenue · quarter$431.3M+50.1% YoY
Diluted EPS$1.83—
P/E · TTM—P/S 6.5×
Net margin12.9%Gross 100.0%
Dividend yieldNone
52-week range396.32 – 602.83−33.6% from high
Volume2.3M5.84× 20-day avg
Volatility · 60d34.1%Annualised
Short % of float14.7%7.2 days to cover
Net cash$619.7MCash $961.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.1%1M −19.3%3M −21.5%6M −25.8%YTD −31.2%1Y −2.9%3Y +217.4%5Y +439.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum50
Revenue growth79
Net margin82
Value (low P/E)—
Size94

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.2M−8.4% vs prior
Days to cover7.2Settled Oct 15
% of float14.7%
Short vol. 10d46.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25B
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84BCompare
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
BMRNBioMarin Pharmaceuticals$57.13+2.64%+4.6%+19.9%4.5%151.5$11.06BCompare

News about Madrigal Pharmaceuticals

All news →
Will Madrigal (MDGL) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research · Oct 27, 2026▼ NegativeMadrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026GlobeNewswire Inc. · Apr 22, 2026▲ PositiveMadrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA ProgramsGlobeNewswire Inc. · Feb 11, 2026▲ Positive

Quick answers

What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
What is MDGL's market cap?
$9.25B, based on the Nov 4 close of $400.43.
Does Madrigal Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MDGL is sold short?
2.2M shares, 14.7% of float, as of Oct 15, 2026.
What sector is MDGL in?
Healthcare, in the Pharmaceuticals industry.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

HQ: West Conshohocken, PA915 employeesListed Feb 6, 2007madrigalpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology